Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway

Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254

Cheville, 2002, Metastatic prostate carcinoma to bone: Clinical and pathologic features associated with cancer-specific survival, Cancer, 95, 1028, 10.1002/cncr.10788

Zimmerman, 2002, The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis, Crit Care Med, 30, S294, 10.1097/00003246-200205001-00020

Melnikova, 2007, Inflammation and melanoma growth and metastasis: The role of platelet-activating factor (PAF) and its receptor, Cancer Metastasis Rev, 26, 359, 10.1007/s10555-007-9092-9

Bussolati, 2000, PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis, Am J Pathol, 157, 1713, 10.1016/S0002-9440(10)64808-0

Fallani, 2006, Platelet-activating factor (PAF) is the effector of IFN gamma-stimulated invasiveness and motility in a B16 melanoma line, Prostaglandins Other Lipid Mediat, 81, 171, 10.1016/j.prostaglandins.2006.09.004

Chen, 2015, Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma, Oncogene, 34, 5114, 10.1038/onc.2014.434

Yu, 2014, Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells, J Hematol Oncol, 7, 39, 10.1186/1756-8722-7-39

Giaginis, 2014, Platelet-activating factor (PAF) receptor expression is associated with histopathological stage and grade and patients' survival in gastric adenocarcinoma, Neoplasma, 61, 309, 10.4149/neo_2014_040

Axelrad, 2004, Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration, FASEB J, 18, 568, 10.1096/fj.03-0479fje

Melnikova, 2006, Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis, J Biol Chem, 281, 2911, 10.1074/jbc.M508683200

Zhang, 2010, Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium, Reprod Biol Endocrinol, 8, 74, 10.1186/1477-7827-8-74

Yu, 2014, The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: A novel target for combination therapy, Br J Cancer, 111, 515, 10.1038/bjc.2014.323

Melnikova, 2009, Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis, J Biol Chem, 284, 28845, 10.1074/jbc.M109.042150

Hackler, 2014, Systemic platelet-activating factor receptor activation augments experimental lung tumor growth and metastasis, Cancer Growth Metastasis, 7, 27, 10.4137/CGM.S14501

Kitagawa, 2007, Expression of platelet-activating factor receptor: A novel prognosticator in patients with hepatocellular carcinoma following hepatectomy, Oncology, 72, 381, 10.1159/000113149

Jan, 2004, Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells, Cell Signal, 16, 959, 10.1016/j.cellsig.2004.01.011

Littlepage, 2010, Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression, Cancer Res, 70, 2224, 10.1158/0008-5472.CAN-09-3515

Slavin, 2014, Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3, Carcinogenesis, 35, 1301, 10.1093/carcin/bgt488

Zhu, 2014, Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression, Oncol Rep, 31, 2049, 10.3892/or.2014.3060

Yamashita, 2014, The importance of matrix metalloproteinase-3 in respiratory disorders, Expert Rev Respir Med, 8, 411, 10.1586/17476348.2014.909288

Canel, 2013, E-cadherin-integrin crosstalk in cancer invasion and metastasis, J Cell Sci, 126, 393, 10.1242/jcs.100115

Davies, 1998, E-cadherin and associated molecules in the invasion and progression of prostate cancer, Oncol Rep, 5, 1567

Khamis, 2012, Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: Their prospects as therapeutic agents, Med Res Rev, 32, 1026, 10.1002/med.20232

Samatar, 2014, Targeting RAS-ERK signalling in cancer: Promises and challenges, Nat Rev Drug Discov, 13, 928, 10.1038/nrd4281

De Luca, 2012, The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin Ther Targets, 16, S17, 10.1517/14728222.2011.639361

McCubrey, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim Biophys Acta, 1773, 1263, 10.1016/j.bbamcr.2006.10.001

Sosa, 2011, ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease, Clin Cancer Res, 17, 5850, 10.1158/1078-0432.CCR-10-2574